3438-49-1Relevant academic research and scientific papers
Organometallic complex, light-emitting element, light-emitting device, electronic appliance, and lighting device
-
Page/Page column 43; 44; 51; 52; 59; 65; 70; 71, (2018/11/22)
A light-emitting element including a phosphorescent organometallic complex is provided. The organometallic complex emits phosphorescence in the yellow green to orange wavelength range and has high emission efficiency and high reliability. Thus, the organo
Phosphorescent organometallic iridium complex, light-emitting element, light-emitting device, electronic device, and lighting device
-
Page/Page column 39; 40, (2015/01/16)
As a novel substance having a novel skeleton, provided is a novel phosphorescent organometallic iridium complex that can emit phosphorescence in a blue green to red wavelength region and has high emission efficiency. The phosphorescent organometallic irid
Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device
-
Paragraph 0478, (2013/07/05)
As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an orga
Light-Emitting Element, Light-Emitting Device, Electronic Device, Lighting Device, and Novel Organic Compound
-
Paragraph 0710; 0717, (2013/03/26)
A light-emitting element includes an EL layer between a pair of electrodes. The EL layer contains a first compound and a second compound. The first compound is a phosphorescent iridium metal complex having a LUMO level of greater than or equal to ?3.5 eV
INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR
-
Page/Page column 40-41, (2011/05/05)
This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof.
SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS
-
Page/Page column 171; 172, (2008/06/13)
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INHIBITORS
-
Page/Page column 254, (2010/02/13)
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS
-
Page/Page column 290-291, (2010/02/14)
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.
The Chichibabin amination of 4-phenyl- and 4-tert-butyl-pyrimidine
Breuker, J.,Plas, H. C. van der
, p. 367 - 372 (2007/10/02)
During a study on the amination of 4-phenylpyrimidine in potassium amide/liquid ammonia it was found that the extent to which the SN(ANRORC) mechanism operates in the amination largely depends upon whether an ammonium salt is used in quenching the reaction.The composition of the ?-adduct mixture, the structure of the open-chain intermediates, the inhibition of the SN(ANRORC) mechanism and the course of the amination in apolar solvents have been investigated.In addition, it has been found that, in the amination of 4-tert-butylpyrimidine, the SN(ANRORC) mechanism occurs to only a very limited extent.
